This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Farma, Italy.
Reference
Mangia PP, et al. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year. Clinical Drug Investigation : 31 Jul 2021. Available from: URL: http://doi.org/10.1007/s40261-021-01067-w
Rights and permissions
About this article
Cite this article
Fixed-combination indacaterol acetate, glycopyrronium, mometasone cost effective for adults with poorly controlled asthma in Italy. PharmacoEcon Outcomes News 885, 9 (2021). https://doi.org/10.1007/s40274-021-07951-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07951-x